Vaccine Prospectus: National Immunisation Programme and vaccine products
In plain English
The notice doesn't say
Who holds it now
Last won by Astrazeneca UK Limited in Jun 2026.
- Live Attenuated Influenza Vaccine 2026/2027Astrazeneca UK Limited
- Rabies Vaccine (2026)Bavarian Nordic UK Ltd £1
- Human Papillomavirus (HPV) vaccine (2025)Merck Sharpe and Dohme (UK) Limited
What you're up against
- The last two awards went to different firms: this buyer has changed supplier before.
- 3 different firms won this buyer's 3 awards for this kind of work since 2025.
The notice as published
Improving health outcomes through vaccines is a priority for the UK Health Security Agency (UKHSA). We aim to use UKHSA's capabilities across the full vaccine pathway to facilitate innovation and support the development and deployment of safe and effective vaccines, ensure the reliable and timely procurement, storage and distribution of vaccines, and drive increased uptake among the population to reduce the burden of infectious disease. UKHSA published a Vaccine Prospectus in August 2026, which sets out the work that UKHSA and the wider health family do to sustain and grow the UK's world-leading role in immunisation. It details the scope of our programmes, our policy objectives, how we work with industry, and forthcoming opportunities to work with us. The publication can be accessed here: https://www.gov.uk/government/publications/vaccine-prospectus-national-immunisation-programme-and-vaccine-products